Vitamin D2 May Lower Your Vitamin D3 Levels, Large Review Finds

Banks reported, chips slid and the indexes barely moved. The S&P 500 slipped just 1.79 points.

The quick scan: Tuesday was a session of cancelling forces. All three major indexes ended a touch lower, with the S&P 500 and NASDAQ down less than a quarter of a percent and the Dow giving up about a third of a percent. Bank earnings were the main event: Goldman Sachs beat estimates, JPMorgan came in below its profit estimate and Wells Fargo missed on revenue. Chip stocks, led by Micron, weighed on tech. The 10-year Treasury yield eased to about 5.2% as bond trading resumed after Monday's holiday. Attention now turns to this morning's consumer price report.

S&P 500: -0.02% to 7,805.45 – Down 1.79 points, essentially flat; Micron was the heaviest single drag, and gains elsewhere offset losses in banks and chips
Dow Jones: -0.35% to 51,670.10 – Fell 180.45 points; Wells Fargo dropped 3.1% and JPMorgan 0.9%, while Goldman Sachs slipped 0.2% despite beating estimates
NASDAQ: -0.15% to 27,204.38 – Fell 41.52 points as chip stocks, especially memory makers, weakened.

What's driving it: Earnings season has started with the banks, and the early read is mixed. Corporate results topped analysts' expectations overall, but those gains were offset by disappointments elsewhere, which left the indexes close to record levels yet going nowhere. A flat headline number hid sharper moves underneath, with Goldman Sachs and others swinging between gains and losses after reporting. Bonds provided a calmer backdrop. Trading resumed after the Monday holiday, and the 10-year yield eased from 5.24% to 5.21%, still above the 5% mark. The consumer price report is due this morning, and a data release like that often keeps traders from taking big positions the day before, which would fit a session this quiet. The reading matters for retirees because inflation feeds directly into rate expectations, bond yields and cost-of-living adjustments. For now, the market is waiting for the number.

Bottom line: A flat index can hide a lot of movement underneath, and Tuesday was a good example. For L-Plate Retirees, the habit worth building is looking past the headline number, whether in a portfolio or a supplement cabinet. Nothing in Tuesday's session called for action, and a quiet day before a data release is a reasonable time to do nothing.

Vitamin D2 or D3? The Label on Your Bottle May Matter More Than You Think

The scoop: Picture yourself in the supplement aisle, holding two bottles of vitamin D that look almost identical. One label says D2. The other says D3. You pick the cheaper one, or the one with the friendlier font, and you carry on with your day. Most of us have done exactly that.

A University of Surrey team has been looking at whether the choice matters. Their meta-analysis, published in Nutrition Reviews in 2025 and written up again by ScienceDaily this month, found that taking vitamin D2 can lower the amount of vitamin D3 in your blood. Emily Brown, the lead researcher, called it "a previously unknown effect."

A quick note on framing before we go further. This is an established body of evidence, not breaking news, and nothing here is advice to start, stop or switch a supplement. If you take D2 on a doctor’s instruction, that point is for you in particular.

Two vitamins sharing one name

Vitamin D2, also called ergocalciferol, is usually made from fungi or yeast exposed to ultraviolet light. Vitamin D3, or cholecalciferol, is the form your skin makes when sunlight lands on it. In supplements, D3 has traditionally been sourced from lanolin, the natural grease in sheep's wool, though animal-free versions made from lichen are also available.

Your liver converts either form into 25-hydroxyvitamin D. That is the number measured in a blood test. It comes in two versions, written 25(OH)D2 and 25(OH)D3, depending on which vitamin it started as.

What the review found

The researchers reviewed 20 studies and pooled the randomised controlled trials, 11 of them in the main analysis. People who took D2 had significantly lower 25(OH)D3 than people who did not. The average reduction was roughly 9 to 18 nmol/L, depending on how the data were analysed. That is an average across the trials, so any one person's result could sit above or below it. A nmol/L is simply the unit blood labs use to report how much of a substance is circulating.

Now the part that stops this from being a scare story. D2 still raises 25(OH)D2, and it still contributes to your total vitamin D status. The finding is not that D2 does nothing. It is that D2 appears to pull your D3 level down while it goes about its work.

Why would that happen?

Nobody knows yet. The mechanism is unexplained. One hypothesis is that when vitamin D levels rise, the body speeds up the breakdown of vitamin D metabolites, and D3 gets caught in that clean-up. Earlier work suggests the reverse can happen too, with D3 lowering D2 metabolites. So this may be a general quirk of how the body handles the vitamin, not a flaw in one form.

D2 is not the villain

A separate 2026 meta-analysis of 26 randomised trials found that D2 significantly reduced parathyroid hormone and slightly raised blood calcium. That tells us D2 is biologically active. Nothing in this research says D2 is harmful or ineffective. The finding is narrower than that.

What the research does say is that D3 tends to come out ahead. The US National Institutes of Health notes that both forms raise blood vitamin D, but D3 raises it more and for longer. An earlier meta-analysis of 24 studies reached the same conclusion. Most of the coverage is university and institute press material, not independent reporting. Brown's own summary is carefully hedged: "subject to personal considerations, vitamin D3 supplements may be more beneficial for most individuals over vitamin D2."

“Personal considerations” is the phrase to underline: the researchers are leaving room for your own doctor’s judgement.

A related finding, read with care

A separate Surrey study, published in Frontiers in Immunology and led by Professor Colin Smith, found that D3 but not D2 stimulated type I interferon signalling. You may see this reported as D3 helping to fight infection. The researchers themselves caution that it is not proof of fewer infections. It is a finding about gene activity, and gene activity is a long way from a fewer-colds claim. For now it is a lead for researchers to chase, not a benefit you can bank.

The question nobody has answered

Here is what we know, and what we do not. We know that taking D2 lowers D3 levels in the blood. We do not yet know whether that reduction changes any health outcome. It may matter. It may be a blip on a lab report with no consequence for how you feel, how your bones hold up, or anything else. The research has not said.

That gap is the centre of this story, and until that gap is filled, the finding stays a question, not a verdict. A measurable change in a blood marker is interesting. A change in how people actually fare is what we would need before anyone rewrote their medicine cabinet.

Why your own situation comes first

Some people take D2 because a doctor prescribed it. There are good reasons a prescriber might choose it, and the meta-analysis does not know your history, your bloodwork or your other medications. If you are in that group, a headline is not a reason to swap. A conversation is.

For everyone else, the practical shift is small but real. The vitamin D bottle in your bathroom cabinet is not a generic. It has a form, and the form is on the label. Reading it takes ten seconds, which is about nine seconds longer than most of us have ever spent on a supplement.

We spend weeks comparing laptops and seconds on the supplement that sits next to our toothbrush for years.

So if this left you curious, take it to the people who know your history. Your doctor or pharmacist can tell you which form you are on, why, and whether it is worth a second conversation.

Actionable takeaways for L-Plate Retirees:

• Read the label on your vitamin D bottle. Look for D2 (ergocalciferol) or D3 (cholecalciferol). Many of us have never checked, and knowing which one you take is the first step to a useful conversation with your doctor or pharmacist. Snap a photo of the label if you tend to forget.

• Do not switch or stop on your own. Some people are prescribed D2 for good reasons. This research is not a recommendation to change anything, and a pharmacist can tell you in a minute whether your situation is one of those. If you are unsure why you take what you take, that is a fine question to ask.

• Bring it to your next appointment as a question. Something like: "I read that D2 may lower D3 levels in the blood. Does that matter for me?" It costs nothing, and your doctor knows your bloodwork and your history. Write the question down beforehand, because appointments have a way of ending before we remember it.

• Remember that D2 is active, not useless. It raises 25(OH)D2 and contributes to total vitamin D status, and a 2026 analysis found it lowers parathyroid hormone. The finding is about a trade-off in blood levels, not about D2 failing.

• Treat the interferon result as a curiosity, not a cold remedy. D3 stimulated a type of immune signalling in one lab study, but the researchers say it does not prove fewer infections. Nothing here supports a claim that D3 prevents illness.

• Hold the open question open. Nobody yet knows whether a lower D3 level changes any health outcome. Be wary of anyone who claims they do, whether they are selling D2, D3 or a fear of both.

Your Turn: Do you know which form of vitamin D you take, and how did you choose it in the first place? If your doctor had prescribed D2, would a headline like this make you question it, or would you ask about it first? What other supplement in your cabinet have you taken for years without ever reading past the front of the bottle?

👉 Hit reply and share your thoughts – your answers could inspire fellow readers in future issues.

☕ If this issue helped you see that two bottles that look the same on the shelf can behave differently in the body, consider shouting L-Plate Retiree a coffee on Ko-fi. Your support keeps these plain-English looks at the evidence coming.